4D Molecular Therapeutics (FDMT) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
4D Molecular Therapeutics (FDMT) has outperformed Sana Biotechnology (SANA) over the past year, gaining 31.5% versus a loss of 38.4%. Over five years, FDMT leads with a -53.5% price change compared with -86.6% for SANA. Sana Biotechnology is the larger company by market cap ($835.2 million vs $701.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FDMT | SANA |
|---|---|---|
| Share price | $12.70 | $2.79 |
| Market cap | $701.60M | $835.22M |
| 1-day change | +0.87% | +2.57% |
| YTD return | +69.33% | -31.45% |
| 1-year return | +31.47% | -38.41% |
| 5-year return | -53.51% | -86.58% |
| EPS (TTM) | $-2.63 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.93 | $6.55 |
| 52-week low | $6.96 | $2.61 |
| Distance from 52-week high | -24.99% | -57.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +121.18% | +202.15% |
| Average volume | 926.78K | 3.13M |
| Shares outstanding | 55.24M | 299.36M |
| Employees | 196 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FDMT has outperformed SANA by 69.9 percentage points over the past year.
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
FDMT vs SANA FAQ
Which is bigger, 4D Molecular Therapeutics or Sana Biotechnology?
Sana Biotechnology (SANA) is larger, with a market capitalization of $835.22M compared with $701.60M for 4D Molecular Therapeutics (FDMT).
Which stock has performed better over the past year, FDMT or SANA?
FDMT returned +31.47% over the past 12 months, compared with -38.41% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are 4D Molecular Therapeutics and Sana Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.